Evidence map›Paper›PMID 26284588›Full record

ArticleOncotarget2015

Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster.

Huafei Li, Ge Zhang, Cheng Jiang, Fulei Zhang, Changhong Ke, He Zhao, Yun Sun, Mengxin Zhao, Di Chen, Xiandi Zhu and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Huafei LiInternational Joint Cancer Institute, the Second Military Medical University, Shanghai, China.
Ge ZhangInternational Joint Cancer Institute, the Second Military Medical University, Shanghai, China.
Cheng JiangInternational Joint Cancer Institute, the Second Military Medical University, Shanghai, China.
Fulei ZhangInternational Joint Cancer Institute, the Second Military Medical University, Shanghai, China.
Changhong KeInternational Joint Cancer Institute, the Second Military Medical University, Shanghai, China.
He ZhaoInternational Joint Cancer Institute, the Second Military Medical University, Shanghai, China.
Yun SunInternational Joint Cancer Institute, the Second Military Medical University, Shanghai, China.
Mengxin ZhaoInternational Joint Cancer Institute, the Second Military Medical University, Shanghai, China.
Di ChenInternational Joint Cancer Institute, the Second Military Medical University, Shanghai, China.
Xiandi ZhuInternational Joint Cancer Institute, the Second Military Medical University, Shanghai, China.
Li ZhangInternational Joint Cancer Institute, the Second Military Medical University, Shanghai, China.
Bohua LiInternational Joint Cancer Institute, the Second Military Medical University, Shanghai, China.
Jianxin DaiInternational Joint Cancer Institute, the Second Military Medical University, Shanghai, China.
Wei LiInternational Joint Cancer Institute, the Second Military Medical University, Shanghai, China.
Second Military Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the anti-CD20 antibody Rituximab has revolutionized the treatment of Non-Hodgkin Lymphoma (NHL), resistance to treatment still existed. Thus, strategies for suppressing Rituximab-resistant NHLs are urgently needed. Here, an anti-CD20 nanocluster (ACNC) is successfully constructed from its type I and type II mAb (Rituximab and 11B8). These distinct anti-CD20 mAbs are mass grafted to a short chain polymer (polyethylenimine). Compared with parental Rituximab and 11B8, the ACNC had a reduced "off-rate". Importantly, ACNC efficiently inhibited Rituximab-resistant lymphomas in both disseminated and localized human NHL xenograft models. Further results revealed that ACNC is significantly potent in inducing caspase-dependent apoptosis and lysosome-mediated programmed cell death (PCD). This may help explain why ACNC is effective in suppressing rituximab-resistant lymphoma while Rituximab and 11B8 are not. Additionally, ACNC experienced low clearance from peripheral blood and high intratumor accumulation. This improved pharmacokinetics is attributed to the antibody-antigen reaction (active targeting) and enhanced permeability and retention (ERP) effect (passive targeting). This study suggested that ACNC might be a promising therapeutic agent for treatment of rituximab-resistant lymphomas.

Indexed as

AnimalsAntibodies, MonoclonalAntigens, CD20Antineoplastic AgentsApoptosisCaspasesCell AdhesionCell Line, TumorEnzyme ActivationFemaleHumansLymphoma, B-CellLymphoma, Non-HodgkinLysosomesMembrane Potential, MitochondrialMiceAntibodies, MonoclonalAntigens, CD20Antineoplastic AgentsCaspasesPolyethyleneiminePolymersRituximabapoptosisCD20nano mAb’s clusternon-Hodgkin lymphomaRituximab

Identifiers

PMID26284588
PMCPMC4695179
OpenAlexW1942035847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.